Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bluejay Diagnostics, Inc.BJDX · Entity 8627 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bluejay Diagnostics, Inc.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2031-08-17 | Direct | 100,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 100,000 · Balance 100,000 F1: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MERCHANTS BANCSHARES INC
Report date May 12, 2017 · Filed May 16, 2017
Section 16 reporting ended · disclosed 2017-05-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-05-12 transaction · row 1
1 source rowRow 1 · 2017-05-12 · Disposition to issuer · Disposed 29,648 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 22, 2016 (the "Merger Agreement"), between Merchants Bancshares, Inc. ("Merchants") and Community Bank System, Inc. ("Community Bank System"). Pursuant to the Merger Agreement, in exchange for each share of Merchants common stock the reporting person could elect to receive (i) $40.00 per share in cash without interest, (ii) 0.9630 shares of Community Bank System common stock, or (iii) a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock. F2: Any election by the reporting person is subject to proration procedures that are designed to ensure that the total amount of cash paid, and the total number of shares of Community Bank System common stock issued, in the merger will equal as nearly as practicable the total amount of cash and number of shares that would have been paid and issued if all of the Merchants stockholders received a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 22, 2016 (the "Merger Agreement"), between Merchants Bancshares, Inc. ("Merchants") and Community Bank System, Inc. ("Community Bank System"). Pursuant to the Merger Agreement, in exchange for each share of Merchants common stock the reporting person could elect to receive (i) $40.00 per share in cash without interest, (ii) 0.9630 shares of Community Bank System common stock, or (iii) a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock.
F2: Any election by the reporting person is subject to proration procedures that are designed to ensure that the total amount of cash paid, and the total number of shares of Community Bank System common stock issued, in the merger will equal as nearly as practicable the total amount of cash and number of shares that would have been paid and issued if all of the Merchants stockholders received a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 20:15 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001123292-26-001123 · form4.xml · derivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device. Read SEC document |
| March 14, 2026 Filed May 18, 2026 21:20 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | PurchaseCommon Stock | 12,500 | $2.00 | $25,000.00 |
DisclosureSEC source: 0001123292-26-000688 · form4.xml · nonDerivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,525 F1 · shares: On March 14, 2026, Mr. Chase purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share. Read SEC document |
| February 01, 2023 Filed Feb 13, 2023 22:42 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantCommon Stock | 27,500 | $0.44 | $12,100.00 |
DisclosureSEC source: 0001213900-23-010890 · ownership.xml · nonDerivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,852 Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 22:16 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 2,500 | Not disclosed Strike: $1.26 | Not disclosed |
DisclosureSEC source: 0001213900-22-014586 · ownership.xml · derivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,262 Underlying: Common Stock · 2,500 shares Expires 2032-03-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on December 15, 2022, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| January 10, 2022 Filed Jan 14, 2022 00:30 UTC | Bluejay Diagnostics, Inc. BJDX · Entity 8627 | GrantOption to purchase common stock · Derivative | 25,000 | Not disclosed Strike: $2.79 | Not disclosed |
DisclosureSEC source: 0001213900-22-002005 · ownership.xml · derivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,762 Underlying: Common Stock · 25,000 shares Expires 2032-01-10 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on December 15, 2022, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| May 12, 2017 Filed May 16, 2017 18:57 UTC | MERCHANTS BANCSHARES INC MBVT · Entity 176117 | Disposition to issuerCommon Stock | 29,648 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-033259 · a4.xml · nonDerivative · entry 1 CHASE DONALD R · CIK 0001247473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 22, 2016 (the "Merger Agreement"), between Merchants Bancshares, Inc. ("Merchants") and Community Bank System, Inc. ("Community Bank System"). Pursuant to the Merger Agreement, in exchange for each share of Merchants common stock the reporting person could elect to receive (i) $40.00 per share in cash without interest, (ii) 0.9630 shares of Community Bank System common stock, or (iii) a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock. F2 · price: Any election by the reporting person is subject to proration procedures that are designed to ensure that the total amount of cash paid, and the total number of shares of Community Bank System common stock issued, in the merger will equal as nearly as practicable the total amount of cash and number of shares that would have been paid and issued if all of the Merchants stockholders received a combination of $12.00 per share in cash without interest and 0.6741 shares of Community Bank System common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.